Abstract
BackgroundAccording to Danish national guidelines issued in 2015, pts (pts) with inflammatory rheumatic diseases in routine care treatment with originator infliximab (INX) must switch to the cheaper biosimilar infliximab (CT-P13)....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have